TAMPA, Fla.--(BUSINESS WIRE)--As Neutra Corp. (OTCQB: NTRR) continues working to become a major service and technology provider in the nation’s fastest-growing industry, the company’s joint venture partner is close to securing two high-profile opportunities to introduce its products into important new markets.
Last month, NTRR formed a joint venture with Green Mountain Plant Health, LLC, to supply a suite of horticultural products that can help control—and potentially eliminate—plant contaminates such as molds without the use of harsh chemicals in indoor cannabis grows. With the help of another joint venture partner, Surface to Air Solutions (S2O2), NTRR is offering cannabis growers and other businesses new technologies designed to reduce or eliminate the industry’s reliance upon pesticides to produce healthy crops.
Now, Green Mountain Plant Health (GMPH) is in discussions to run two new test studies on cannabis grows in Alaska and Oregon, the two latest states to allow regulated cannabis sales for adult use. The test studies are intended to serve as crucial demonstrations to growers in these important markets that the suite of technologies being marketed by NTRR and S2O2 are capable of producing stronger, healthier and more potent crops than the use of harsh, chemical pesticides.
“Alaska and Oregon are two states where these products have not yet launched, and getting them there was a major priority for us,” said NTRR CEO Chris Brown. “The relationships we intend to forge with growers there could lead to significant contracts throughout the Northwest. We look forward to seeing Green Mountain Plant Health open branch offices in both states.”
About Neutra Corp.
Neutra Corp. is a healthy lifestyle company that specializes in the development and marketing of natural wellness solutions, including cannabis-related products. By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals (OTCBB: GWPRF), INSYS Therapeutics, Inc. (NASDAQ: INSY) and ENDEXX Corp. (OTCBB: EDXC), delivering technological advancements in the cultivation and processing of cannabis in approved markets. For investing information and performance data, please visit www.neutracorp.com.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.